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Abstract
Black tea consumption has been associated with many health benefits including the prevention of
cancer and heart disease. Theaflavins are the major bioactive polyphenols present in black tea.
Unfortunately, limited information is available on their biotransformation. In the present study, we
investigated the metabolic fate of theaflavin 3,3′-digallate (TFDG), one of the most abundant and
bioactive theaflavins, in mouse fecal samples using liquid chromatography/electrospray ionization
tandem mass spectrometry by analyzing the MSn (n = 1–3) spectra. Four metabolites theaflavin,
theaflavin 3-gallate, theaflavin 3′-gallate, and gallic acid were identified as the major mouse fecal
metabolites of TFDG. Glucuronidated and sulfated, instead of methylated metabolites of
theaflavin 3-gallate, theaflavin 3′-gallate, and TFDG were detected and identified as the minor
mouse fecal metabolites of TFDG. Our results indicate that TFDG can be degraded in mice.
Further studies on the formation of those metabolites in TFDG-treated mice in germ-free
conditions are warranted. To our knowledge, this is the first report on the biotransformation of
TFDG in mice.
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1. Introduction
As a popular beverage, tea (Camellia sinensis, Theaceae) has been associated with many
beneficial health effects, including the prevention of cancer and heart disease [1–3], a
phenomenon mostly attributed to the presence of polyphenolic compounds. There are three
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principal types of tea, namely green (unfermented), oolong (partially fermented) and black
(fully fermented) tea, the latter representing ~78% of worldwide tea production. The main
polyphenols in black tea are theaflavins and thearubigins, which are formed by the oxidation
and polymerization of catechins in tea leaves during fermentation. Theaflavins including
theaflavin (TF), theaflavin-3-gallate (TF3G), theaflavin-3′-gallate (TF3′G), and
theaflavin-3,3′-digallate (TFDG) (Fig. 1), possess a benzotropolone skeleton that is formed
from co-oxidation of selected pairs of catechins. Thearubigins, which have higher molecular
weights, are poorly characterized chemically. In black tea, catechins, theaflavins and
thearubigins account for 3–10%, 2–6%, and greater than 20%, respectively, of the water-
extractable material by dry weight [4–6].
Recently, theaflavins have received extensive attention due to their antioxidative, anti-
inflammatory, and anti-tumor activities [7,8]. Theaflavins have been shown to scavenge
hydroxyl radicals with TFDG being the most active component [9] and to inhibit lipid
oxidation detected in the rabbit erythrocyte ghost system [10] and in rat liver homogenates
[11]. Studies have demonstrated that TFDG blocks nitric oxide synthase by down-regulating
the activation of NF-κB and suppresses lipopolysaccharide-induced NF-κB activity through
down-regulation of IκB kinase activity in macrophages [12,13]. Theaflavins (0.1% in
drinking fluid) significantly reduced tumor multiplicity and volume by 23% and 34%,
respectively, in 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis
in A/J mice [14]. Oral administration of TFDG (5 mg/kg daily i.g.) significantly improved
trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice and inhibited production of
inflammatory mediators through a mechanism that involves inhibition of NF-κB activation
[15]. The C3(1)/SV40 T-antigen transgenic mice treated with theaflavins (0.05% in drinking
fluid) survived longer and had smaller breast tumors as compared to control mice [16].
It has been reported, however, that theaflavins have poor systematic bioavailability. Mulder
et al. reported that the Cmax of theaflavin in human plasma and urine was only 1 ng/mL and
4.2 ng/mL, respectively, following consumption of 700 mg of a pure mixture of theaflavins,
which is equivalent to about 30 cups of black tea [17]. Neither theaflavin mono- nor di-
gallates were detectable in this study. Very limited amounts of TFDG (<1 nmol/g tissue)
were detected in tissue samples collected from mice treated with decaffeinated black tea (50
mg/g diet) for two weeks [18]. Therefore, it is puzzling how theaflavins, especially TFDG,
can exert their biological protective functions despite such low bioavailability. Studies have
shown that higher molecular weight polyphenols are metabolized by the microbiota and that
their metabolites may play an important role in their health benefits [19–21]. Clearly, a
comprehensive understanding of TFDG metabolism is essential to understanding the health
benefits conferred by this compound as well as black tea. To our knowledge, there is no
report on the biotransformation of theaflavins. In recent years, liquid chromatography/
tandem mass spectrometry (LC/MS/MS) has evolved as a valuable tool for structural
analysis of the metabolites of many bioactive polyphenols. In the present study, we analyzed
the metabolic profile of TFDG from mouse feces using liquid chromatography/electrospray
ionization (ESI) tandem mass spectrometry. The structures of eight major metabolites were
identified by analyzing the MS2 and MS3 spectra of each compound.
2. Experimental
2.1. Materials
TF, TF3G, TF3′G, and TFDG were prepared previously in our laboratory [22]. Gallic acid
was purchased from Sigma-Aldrich (St. Louis, MO, USA). LC/MS-grade solvents and other
reagents were obtained from Fisher Scientific (Pittsburgh, PA, USA).
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2.2. Treatment of mice and feces collection
Experiments with mice were carried out according to a protocol approved by the
Institutional Review Board for the Animal Care and Facilities Committee at North Carolina
Central University. Female C57BL/6J mice were purchased from the Jackson Laboratory
(Bar Harbor, ME, USA) and allowed to acclimate for at least 1 week prior to the start of the
experiment. The mice were housed 5 per cage and maintained in air-conditioned quarters
with a room temperature of 20 ± 2 °C, relative humidity of 50 ± 10%, and an alternating 12-
h light/dark cycle. Mice were fed Purina Rodent Chow #5001 (Research Diets) and water,
and were allowed to eat and drink ad libitum. TFDG in dimethyl sulfoxide (DMSO) was
administered to mice by oral gavage (200 mg/kg). Feces and urine samples were collected in
metabolism cages (5 mice per cage) for 24 h after administration of vehicle (control group, n
= 5) or TFDG (treated group, n = 5). These samples were stored at –80 °C before analysis.
2.3. Fecal and urine sample preparation
For the metabolic profile, four pieces of each fecal sample (control and treated) were chosen
and put into 2 mL tubes. Each set was weighed (control: 75.0 mg and treated: 77.0 mg) and
1.0 mL of 50/50 MeOH/water + 0.1% formic acid was added to each sample. Samples were
sonicated for 90 min then vortexed to mix well, then centrifuged at 17 (×1000) rpm for 10
min. 650 μL of the supernatants were removed from the centrifuged samples and transferred
to LC/MS vials for analysis. In order to determine whether TFDG is stable under these
conditions, TFDG in 50/50 MeOH/water + 0.1% formic acid (10 μM) was sonicated for 90
min and then transferred to LC/MS vials for analysis. The urine samples (50 μL from each
group, control group and TFDG-treated group) were added to 200 μL methanol to
precipitate proteins. After centrifugation at 17 (×1000) rpm for 5 min, the supernatant was
transferred into vials for LC/MS analysis.
2.4. HPLC analysis
An HPLC-ECD (ESA, Chelmsford, MA) consisting of an ESA model 584 HPLC pump, an
ESA model 542 autosampler, an ESA organizer, and an ESA coularray detector coupled
with two ESA model 6210 four sensor cells was used in our study. A Gemini C18 column
(150 mm × 4.6 mm, 5 μm; Phenomenex, Torrance, CA, USA) was used for
chromatographic analysis at a flow rate of 1.0 mL/min. The mobile phases consisted of
solvent A (30 mM sodium phosphate buffer containing 1.75% acetonitrile and 0.125%
tetrahydrofuran, pH 3.35) and solvent B (15 mM sodium phosphate buffer containing 58.5%
acetonitrile and 12.5% tetrahydrofuran, pH 3.45). The gradient elution had the following
profile: 0% B from 0 to 10 min; 0–30% B from 10 to 20 min; 30–40% B from 20 to 35 min;
40–50% B from 35 to 50 min; 50–100% B from 50 to 55 min; 100% B from 55 to 59 min;
and then 0%B from 59.1 to 65 min. The cells were then cleaned at a potential of 1000 mV
for 1 min. The injection volume of the sample was 10 μL.
2.5. LC/ESI-MS method
LC/MS analysis was carried out with a Thermo-Finnigan Spectra System which consisted of
an Accela high-speed MS pump, an Accela refrigerated autosampler, and an LTQ Velos ion
trap mass detector (Thermo Electron, San Jose, CA, USA) incorporated with heated
electrospray ionization (H-ESI) interfaces. A Gemini C18 column (50 mm × 2.0 mm i.d., 3
μm; Phenomenex, Torrance, CA, USA) was used for separation of theaflavins and their
potential phase II metabolites at a flow rate of 0.2 mL/min. The column was eluted with
100% solvent A (H2O with 0.1% formic acid) for 3 min, followed by linear increases in B
(acetonitrile with 0.1% formic acid) to 70% from 3 to 48 min and to 100% B from 48 to 49
min, and then with 100% B from 49 to 54 min. The column was re-equilibrated with 100%
A for 5 min. A Kinetex C18 column (100 mm × 4.6 mm i.d., 5 μm; Phenomenex, Torrance,
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CA, USA) was used for separation of phenolic acids and their potential phase II metabolites
at a flow rate of 0.4 mL/min. The column was eluted with 100% solvent A (H2O with 0.1%
formic acid) for 3 min, followed by linear increases in B (acetonitrile with 0.1% formic acid)
to 70% from 3 to 23 min and to 100% from 23 to 24 min, and then with 100% B from 24 to
29 min. The column was re-equilibrated with 100% A for 5 min. The LC eluent was
introduced into the H-ESI interface. The negative ion polarity mode was set for the H-ESI
source with the voltage on the H-ESI interface maintained at approximately 4 kV. Nitrogen
gas was used as the sheath gas and auxiliary gas. To detect the theaflavins and their phase II
metabolites, optimized source parameters, including ESI capillary temperature (300 °C),
capillary voltage (–50 V), ion spray voltage (3.6 kV), sheath gas flow rate (30 units),
auxiliary gas flow rate (5 units), and tube lens (–120 V), were tuned using authentic TFDG.
To detect the phenolic acids and their phase II metabolites, optimized source parameters
were tuned using authentic gallic acid. These parameters include ESI capillary temperature
(300 °C), capillary voltage ( 50 V), ion spray voltage (3.6 kV), sheath gas flow rate (35
units),–auxiliary gas flow rate (15 units), and tube lens (–60 V). The collision-induced
dissociation (CID) for H-ESI was conducted with an isolation width of 2 Da and normalized
collision energy of 35 for MS2 and MS3. Default automated gain control target ion values
were used for MS, MS2, and MS3 analyses. The mass range was from 50 to 1500 m/z. The
mass resolution was 0.6 amu FWHM. Data acquisition was performed with Xcalibur version
2.1.0 (Thermo Electron, San Jose, CA, USA).
3. Results and discussion
The strategy that we used for structural characterization of TFDG metabolites was
knowledge-based metabolic identification. Simple phenols and phenolic acids have been
reported as the microbial-derived degradation products of higher molecular weight
polyphenols [19–21]. In this study, we searched the existence of potential microbial-derived
metabolites of TFDG including TF, TF3G, TF3′G, GA, diHBA, pyrogallol, 3,4-
dihydroxyphenylpropionic acid (diHPP), 3,4-dihydroxyphenylacetic acid (diHPAc), m-
hydroxyphenylacetic acid (m-HPAc), phenylacetic acid (PAc), vanillic acid (VA), m-
hydroxybenzoic acid (mHBA), p-hydroxybenzoic acid (p-HBA), hippuric acid (HA), m-
coumaric acid (m-CA), 4-hydroxyphenyl acetic acid (4-HPAc), 3-methoxy-4-hydroxyphenyl
acetic acid (homo-VA), 5-(3′,4′,5′-trihydroxyphenyl)-γ-valerolactone (M4), 5-(3′,4′-
dihydroxyphenyl)-γ-valerolactone (M6), and their related phase II metabolites.
In addition, glucuronidation, sulfation, and methylation represent the major metabolic
pathways for tea catechins [23]. We predict that TFDG may also be a substrate for
glucuronidation, sulfation, and methylation. Therefore, we also searched the phase II
metabolites of TFDG including TFDG glucuronide (m/z 1044), TFDG sulfate (m/z 948),
mono-methylated TFDG (m/z 882), di-methylated TFDG (m/z 896), mono-methylated
TFDG monoglucuronide (m/z 1058), mono-methylated TFDG mono-sulfate (m/z 962),
TFDG mono-glucuronide and mono-sulfate (m/z 1124), and mono-methylated TFDG mono-
glucuronide and mono-sulfate (m/z 1138).
The fecal and urine samples collected both from control mice and mice treated with 200 mg/
kg TFDG via oral gavage were analyzed by HPLC coupled with electrochemical detector
(ECD) (Fig. 2) as well as negative ESI-MS (Figs. 3–8). Among all the possible metabolites
that we searched, TF, TF3G, TF3′G, and GA were identified as the major metabolites of
TFDG and glucuronidated and sulfated metabolites as the minor metabolites in mouse fecal
samples (Table 1). None of those metabolites were detected from the TFDG positive control
sample indicating that TFDG is stable under the conditions that were used to prepare mouse
fecal samples. We could not detect any metabolites in urine samples from mice treated with
TFDG (data not shown).
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3.1. Identification of gallic acid as metabolite of TFDG
In the HPLC-ECD chromatograms, there was one peak in the fecal samples collected from
TFDG-treated mice had an almost identical retention time as that of authentic gallic acid
(Fig. 2C and E). Further LC/MS analysis confirmed that this peak was gallic acid (Fig. 3A).
There was one peak shown in the fecal samples collected from TFDG-treated mice under the
selected ion monitoring (SIM) mode of m/z 169 [M–H]– (molecular ion of gallic acid under
negative mode). This peak had an almost identical retention time and MS2 spectrum as
authentic gallic acid (Fig. 3A). Therefore, metabolite M1 was identified as gallic acid (Fig.
1).
3.2. Identification of TF, TF3G and TF3′G as metabolites of TFDG
In the extracted chromatogram of m/z 563 [M–H]– (molecular ion of TF under ESI negative
mode), one new peak (M2) was found in the fecal samples collected from TFDG treated
mice (Fig. 3B). Peak M2 (RT: 22.71 min) had a molecular weight of 564 as determined by
the mass ions at m/z 563 [M–H]– and 1127 [2M–H]–, which is the same as that of TF (m/z
564) (spectra were not shown). Then we compared the retention time and the tandem mass
spectrum of peak M2 with those of authentic TF. Our results indicated that they had almost
identical retention times and mass fragments (Fig. 3B). Therefore, peak M2 is identified as
TF (Fig. 1), which lost two gallate groups from TFDG.
In the extracted chromatogram of m/z 715 [M–H]– (molecular ion of TF3G and TF3′G
under ESI negative mode), two new peaks (M3 and M4) were found in the fecal samples
collected from TFDG treated mice (Fig. 4). Peaks M3 and M4 both had a molecular weight
of m/z 716 as determined by the mass ion at m/z 715 [M–H]–. Their retention times and MS/
MS spectra were almost identical to those of authentic TF3G and TF3′G (Fig. 4), indicating
that peaks M3 and M4 are TF3G and TF3′G, respectively, each of which lost one of the two
gallate groups from TFDG (Fig. 1).
In addition, in the extracted chromatogram of m/z 867 [M–H]– (molecular ion of TFDG
under ESI negative mode), one peak was found in the fecal samples collected from TFDG
treated mice (Fig. 3C). This peak had an almost identical retention time and MS2 spectrum
as those of authentic TFDG (Fig. 3C) indicating that there was unmetabolized TFDG in
mouse fecal samples.
Studies have shown that theaflavins, especially TFDG, have poor systematic bioavailability.
TFDG was not detected in human plasma and urine following consumption of 700 mg of a
pure mixture of theaflavins [17] and only trace amounts of TFDG (<1 nmol/g tissue) were
detected in tissue samples collected from mice treated with decaffeinated black tea (50 mg/g
diet) for two weeks [18]. However, in vivo studies have shown that theaflavins have anti-
inflammatory and anti-tumor activities [7,14,15]. Studies have also shown that microbial-
derived metabolites of higher molecular weight polyphenols may play an important role in
their health benefits 19–21]. Therefore, it is possible that the degradation products of TFDG
observed in this study are responsible for the reported beneficial effects of TFDG. Gallic
acid has indeed been reported to have anti-inflammatory and anti-tumor activities [24–29].
However, the impact of this metabolite on the anti-inflammatory and cancer preventive
effects of theaflavins needs to be further studied, especially under in vivo conditions. In
addition, the interplay between microorganisms and theaflavins is a topic for future study.
3.3. Identification of glucuronidated and sulfated metabolites of TFDG
In the extracted chromatogram of m/z 1034 [M–H]– (molecular ion of mono-glucuronidated
TFDG under negative mode), seven major peaks (M5-1–M5-7) were observed from fecal
samples collected from TFDG-treated mice. They all had similar tandem mass spectra with
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m/z 867 (molecular ion of TFDG under negative mode) as the major product ion indicating
that they are potential mono-glucruonidated metabolites of TFDG (Fig. 5). In order to
further confirm that those compounds were the metabolites of TFDG, we compared the MS3
spectra of the product ion m/z 867 of those seven compounds with the MS2 spectrum of
authentic TFDG (Figs. 3c and 5B–H). Our results clearly indicated that the MS3 spectra of
the product ion m/z 867 were almost identical to the MS2 spectrum of authentic TFDG
suggesting that all the seven compounds were the mono-glucuronidated metabolites of
TFDG (Fig. 1). There are 13 hydroxyl groups in the structure of TFDG, in which 11
potential mono-glucuronidated metabolites of TFDG can be formed in theory. Since the
active sites of TFDG for gulcuronition have not been identified, we cannot provide the
structures of metabolites M5-1–M5-7.
Similarly, in the extracted chromatogram of m/z 867 [M–H]– taken from the MS2 data set
obtained from m/z 947 [M–H]– (molecular ion of mono-sulfated TFDG under negative
mode), five peaks (M6-1–M6-5) were observed from the TFDG-treated mouse fecal
samples. This suggested that they were potential mono-sulfated metabolites of TFDG (Fig.
6). The MS3 spectra of the product ion m/z 867 of those five compounds (Fig. 6B–F) and
the MS2 spectrum of TFDG standard (Fig. 3C) showed the same fragment ion mass spectra
indicating that all of those five peaks were the mono-sulfated metabolites of TFDG. At this
stage, we cannot provide the structures of those metabolites.
3.4. Identification of glucuronidated and sulfated metabolites of TF3G and TF3′G
Our results indicated that TFDG was a substrate for glucuronidation and sulfation. We
predicted that TF, TF3G and TF3′G were also substrates for glucuronidation and sulfation.
In the extracted chromatogram of m/z 715 [M–H]– (molecular ion of TF3G and TF3′G
under negative mode) taken from the MS2 data set obtained from m/z 891 [M–H]–
(molecular ion of mono-glucuronidated TF3G or TF3′G under negative mode). Five peaks
(M7-1–M7-5) were observed from the TFDG-treated mouse fecal samples. This indicated
that they were potential mono-glucruonidated metabolites of TF3G or TF3′G (Fig. 7). Then,
we compared the MS3 spectra of the product ion m/z 715 of those five compounds with the
MS2 spectrum of authentic TF3G or TF3′G (Figs. 4 and 7). Our results shown that all of
those compounds had the same fragment ion mass spectra as the authentic TF3G or TF3′G.
From the structure of TF3G or TF3′G, nine potential glucuronidated metabolites can be
formed in theory. We cannot provide the exact structures of metabolites M7-1–M7-5.
Similarly, in the extracted chromatogram of m/z 715 [M–H]– taken from the MS2 data set
obtained from m/z 795 [M–H]– (molecular ion of mono-sulfated TF3G or TF3′G under
negative mode), three peaks (M8-1–M8-3) were observed from the TFDG-treated mouse
fecal samples (Fig. 8A). The MS3 spectra of the product ion m/z present study four major
metabolites were detected in fecal samples collected from mice treated with TFDG. Their
structures were determined using tandem mass spectrometry as well as by comparing with
authentic standards. This is the first report on the biotransformation of TFDG. Our results
indicated that (1) TFDG is extensively metabolized in mice; (2) the major metabolites of
TFDG are TF, TF3G, TF3′G, and GA, which are most likely generated by gut microflora;
and (3) glucuronidation and sulfation but not methylation are the minor biotrasformation
pathway of TFDG. On the basis of metabolites identified in this study, the major metabolic
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Structures of TFDG and its major metabolites and possible biotransformation pathways of
TFDG. TFDG: theaflavin 3,3′-digallate; TF3G: theaflavin 3-gallate; TF3′G: theaflavin 3′-
gallate; TF: theaflavin; GA: gallic acid.
Chen et al. Page 9














HPLC-ECD chromatograms of a mixture of authentic theaflavin (TF), theaflavin 3-gallate
(TF3G), theaflavin 3′-gallate (TF3′G) and theaflavin 3,3′-digallate (A); authentic theaflavin
3,3′-digallate (TFDG) administrated to mice via oral gavage (B); authentic gallic acid (GA)
(C); fecal samples collected from control mice (D); and fecal samples collected from TFDG
treated mice (E).
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(A) LC chromatograms of fecal samples collected from TFDG treated mice as well as
authentic gallic acid (GA) obtained by negative ESI/MS interface extracted with m/z 169
[M–H]–; MS/MS (negative ion) spectra of the major metabolite (M1) corresponding to m/z
169 [M–H]– in fecal samples collected from TFDG treated mice and authentic GA; (B) LC
chromatograms of fecal samples collected from TFDG treated mice as well as authentic TF
obtained by negative ESI/MS interface extracted with m/z 563 [M–H]–; MS/MS (negative
ion) spectra of the major metabolite (M2) corresponding to m/z 563 [M–H]– in fecal
samples collected from TFDG treated mice and authentic TF; and (C) LC chromatograms of
fecal samples collected from TFDG treated mice as well as authentic TFDG obtained by
negative ESI/MS interface extracted with m/z 867 [M–H]–; MS/MS (negative ion) spectra of
the peak corresponding to m/z 867 [M–H]– in fecal samples collected from TFDG treated
mice and authentic TFDG.
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(A) LC chromatograms of fecal samples collected from control mice and TFDG treated mice
as well as a mixture of authentic TF3D and TF3′D obtained by negative ESI/MS interface
extracted with m/z 715 [M–H]–; (B) MS/MS (negative ion) spectra of the two major
metabolites (M3–M4) corresponding to m/z 715 [M–H]– in fecal samples collected from
TFDG treated mice; and (C) MS/MS (negative ion) spectra of authentic TF3G and TF3′G.
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(A) LC chromatograms of fecal samples collected from TFDG treated mice obtained by
negative ESI/MS interface extracted with m/z 1043 [M–H]–; and (B–H) MS/MS (negative
ion) spectra of the seven major metabolites (M5-1–M5-7) corresponding to m/z 1043 [M–
H]– and MS3 spectra of these metabolites corresponding to m/z 867/1043 [M–H]– in fecal
samples collected from TFDG treated mice.
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(A) LC chromatograms of fecal samples collected from TFDG treated mice obtained by
negative ESI/MS interface extracted with m/z 947 [M–H]–; and (B–F) MS/MS (negative
ion) spectra of the seven major metabolites (M6-1–M6-5) corresponding to m/z 947 [M–H]–
and MS3 spectra of these metabolites corresponding to m/z 867/947 [M–H]– in fecal
samples collected from TFDG treated mice.
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(A) LC chromatograms of fecal samples collected from TFDG treated mice obtained by
negative ESI/MS interface extracted with m/z 891 [M–H]–; and (B–F) MS/MS (negative
ion) spectra of the five major metabolites (M7-1–M7-5) corresponding to m/z 891 [M–H]–
and MS3 spectra of these metabolites corresponding to m/z 715/891 [M–H]– in fecal
samples collected from TFDG treated mice.
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(A) LC chromatograms of fecal samples collected from TFDG treated mice obtained by
negative ESI/MS interface extracted with m/z 795 [M–H]–; and (B–D) MS/MS (negative
ion) spectra of the three major metabolites (M8-1–M8-3) corresponding to m/z 795 [M–H]–
and MS3 spectra of these metabolites corresponding to m/z 715/795 [M–H]– in fecal
samples collected from TFDG treated mice.
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Table 1
Major mouse fecal metabolites of TFDG.
Name Peak number RT (min) Molecular weight MS/MS fragments (relative intensity, %)
GA M1 8.30 170 125 (100)
TF M2 22.71 564 545 (100), 519 (47), 425 (34), 407 (57), 379 (47)
TF3G M3 23.49 716 697 (18), 577 (26), 563 (87), 545 (76), 527 (100)
TF3′G M4 23.92 716 697 (28), 577 (31), 563 (100), 545 (68), 527 (33), 407 (56)
Glu-TFDG M5-1 21.69 1044 697 (60), 867 (100), 891 (89)
M5-2 22.06 1044 697 (50), 867 (100), 891 (21)
M5-3 22.65 1044 697 (76), 867 (100), 891 (56)
M5-4 23.16 1044 697 (35), 867 (100), 891 (24)
M5-5 23.43 1044 697 (52), 867 (100), 891 (28)
M5-6 25.03 1044 697 (36), 867 (100), 891 (15)
M5-7 26.04 1044 697 (36), 867 (100), 891 (14)
Sul-TFDG M6-1 18.38 948 867 (100)
M6-2 24.25 948 867 (100)
M6-3 31.94 948 867 (100)
M6-4 32.72 948 867 (100)
M6-5 35.10 948 867 (100)
Glu-TF3G or Glu-TF3′G M7-1 20.88 892 715 (100)
M7-2 21.52 892 715 (100)
M7-3 21.89 892 715 (100)
M7-4 22.58 892 715 (100)
M7-5 24.86 892 715 (100)
Sul-TF3G or Sul-TF3′G M8-1 23.67 796 715 (100)
M8-2 30.12 796 715 (100)
M8-3 32.28 796 715 (100)
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